Broadwood Partners, L.P. Purchases 1,315,339 Shares of OncoCyte Co. (NASDAQ:OCX) Stock

OncoCyte Co. (NASDAQ:OCX) major shareholder Broadwood Partners, L.P. bought 1,315,339 shares of the stock in a transaction on Wednesday, October 2nd. The stock was purchased at an average price of $2.95 per share, for a total transaction of $3,880,250.05. Following the completion of the purchase, the insider now owns 6,244,405 shares of the company’s stock, valued at approximately $18,420,994.75. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

OncoCyte Price Performance

Shares of NASDAQ OCX traded down $0.09 during midday trading on Friday, hitting $2.89. 25,035 shares of the company traded hands, compared to its average volume of 36,869. OncoCyte Co. has a 12-month low of $2.08 and a 12-month high of $4.34. The stock has a 50-day moving average price of $3.07 and a 200 day moving average price of $2.93.

OncoCyte (NASDAQ:OCX) last posted its earnings results on Thursday, August 8th. The company reported ($0.36) earnings per share for the quarter. The firm had revenue of $0.10 million for the quarter. OncoCyte had a negative return on equity of 149.88% and a negative net margin of 3,558.46%.

Wall Street Analysts Forecast Growth

Several brokerages have commented on OCX. StockNews.com initiated coverage on OncoCyte in a research note on Thursday. They issued a “sell” rating for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $4.25 price target on shares of OncoCyte in a research note on Friday, August 9th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $4.06.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.